Skip to content
Bored Studies
RecruitingPhase 2/Phase 3

Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

Vertex Pharmaceuticals Incorporated · with Zai Lab (Shanghai) Co., Ltd. (for China only) · NCT07204275

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–75 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2, Phase 3
Target enrollment
176
US sites recruiting
27
Study start
September 30, 2025
Record last updated
September 18, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of this study is to evaluate the efficacy, safety, and tolerability of povetacicept in participants with primary membranous nephropathy (pMN).

Being studied: Povetacicept; Tacrolimus

Conditions: Primary Membranous Nephropathy

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Key Inclusion Criteria

  • Diagnosed with pMN with confirmatory historical biopsy. If no historical biopsy was performed that confirmed pMN, a biopsy can be performed during Screening to confirm eligibility

Key Exclusion Criteria

  • Hypersensitivity to investigational medicinal product or to any of its excipients

Other protocol defined Inclusion/Exclusion criteria will apply

Recruiting US locations

Study contacts (from the official record)

  • Medical Information · 001-617-341-6777 · medicalinfo@vrtx.com
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept… (NCT07204275) | Bored Studies